Effect of intravenous tirofiban on the radiologic classification of intracranial hemorrhage after endovascular treatment in acute anterior circulation occlusive stroke: results from the RESCUE BT trial.
J Stroke Cerebrovasc DisJul 15, 2026 (epub)
Feng Peng, Chunzhen Zhang, Shuiwen Li et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial from the RESCUE BT study evaluated the impact of intravenous tirofiban on intracranial hemorrhage (ICH) subtypes in 945 patients undergoing endovascular treatment for acute anterior circulation occlusive stroke. The study found that tirofiban treatment was associated with a significantly increased risk of parenchymal hematoma type 2 (PH-2) with an adjusted relative risk of 1.77.
Key findings
- Intracranial hemorrhage occurred in 31.3% of patients, with various subtypes identified.
- Tirofiban treatment was associated with an increased risk of PH-2 (adjusted RR 1.77).
- Tirofiban also increased the risk of any radiologic ICH (adjusted RR 1.25).
- Cardioembolic stroke patients had a higher risk of PH-2 with tirofiban treatment.
Why it matters
Understanding the risks associated with tirofiban in the context of endovascular treatment for stroke is crucial for clinicians. The increased risk of severe ICH subtypes may influence treatment decisions and patient management strategies.